866087-23-2

Basic information

• Product Name: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester
• Synonyms: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester
• CAS NO: 866087-23-2
• Molecular Weight: 585.7
• Mol File: 866087-23-2.mol

Chemical Properties

• CAS DataBase Reference: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester(866087-23-2)
• EPA Substance Registry System: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester(866087-23-2)

Safety Data

• Hazardous Substances Data: 866087-23-2(Hazardous Substances Data)

Upstream product

• 291509-61-0 3-(4-piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one 
• 866087-22-1 (R)-3-(4-Benzyloxy-3,5-dimethyl-phenyl)-2-hydroxy-propionic acid methyl ester 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 168196-87-0 2-benzyloxy-5-bromo-1,3-dimethylbenzene 
• 866087-20-9 3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-oxo-propionic acid 
• 866087-19-6 (Z,E)-2-acetylamino-3-(4-benzyloxy-3,5-dimethyl-phenyl)-acrylic acid methyl ester 
• 910575-44-9 (R)-3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-hydroxy-propionic acid 
• 100-44-7 benzyl chloride 

Downstream Products

• 866087-24-3 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 

Relevant articles and documents

Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions

The invention relates to CGRP-antagonists of general formula (I), wherein R1, R2, R3, R4 and R5 are defined in claim 1, to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures salts and salt hydrates thereof, in particular to 10 salts thereof, which are physiologically compatible with acids or inorganic or organic bases and to compounds of general formula (I), wherein one or several hydrogen atoms are substituted by deuterium. Drugs containing said compounds, the use thereof and a method for the production thereof are also disclosed.

CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I) in which: R1, R2, R3, R4 and X are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts as well as the hydrates of the salts, in particular, their physiologically compatible salts with inorganic or organic acids and bases, and those compounds of general formula (I) in which one or more hydrogen atoms are replaced by deuterium. The invention also relates to medicaments containing these compounds, the use thereof, and to methods for producing them.

2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS

The invention relates to novel CGRP antagonists of general formula (I), in which B, R1 and R2 are defined as cited in claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts, in addition to the hydrates of their salts, in particular their physiologically compatible salts, with inorganic or organic acids or bases. The invention also relates to medicaments containing said compounds, to their use and to a method for their production.